Sarah J. Fleischer
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis.
Journal: European journal of immunology
Published: June 21, 2017
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor.
Journal: Journal of cell communication and signaling
Published: March 08, 2016
Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: June 09, 2015
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Journal: Arthritis research & therapy
Published: January 27, 2015
Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation.
Journal: Arthritis research & therapy
Published: May 09, 2014
Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 23, 2013
CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Journal: Arthritis and rheumatism
Published: December 29, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026